~~<i id='FF96584837'><strike id='FF96584837'><tt id='FF96584837'><pre id='FF96584837'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：leisure time 2025-09-28 00:17:35 Page View：7

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cue Health's Covid
Next article： Medical records are filled with copy

explore

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

'Null' research findings aren't empty of meaning. Let's publish them

APStockEverymedicalresearcherdreamsofdoingstudiesorconductingclinicaltrialsthatgenerateresultssocomp

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Heart disease in astronauts blamed on cosmic radiation

NASATheywereamongthehealthiestpeopleinthecountry,butseveralApolloastronautssuccumbedearlyinlifetohea